Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05818553 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)
A Phase 2 study of SCN2A Encephalopathy and SCN8A Encephalopathy, sponsored by Praxis Precision Medicines.
- Active
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
- 8
- Study locations
NCT05818553: Active Phase 2 study of SCN2A Encephalopathy and SCN8A Encephalopathy, sponsored by Praxis Precision Medicines.
NCT05818553 is a Phase 2 study of SCN2A Encephalopathy and SCN8A Encephalopathy that is active but no longer recruiting, run by Praxis Precision Medicines. The registered enrollment target is 77 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05818553, a Phase 2 study of SCN2A Encephalopathy and SCN8A Encephalopathy, is active but no longer recruiting, sponsored by Praxis Precision Medicines.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
- 8
- Study locations
Study Summary
A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)
Primary Outcome
Changes from baseline in monthly (28-day) motor seizure frequency
Conditions Studied
Interventions
- DRUG PRAX-562
Study Locations (8)
Other
- Praxis Research Site - Tel Litwinsky
- Praxis Research Site - Madrid
- Praxis Research Site - Glasgow
- Praxis Research Site - London
Georgia
- Praxis Research Site - Atlanta
Illinois
- Praxis Research Site - Chicago
Minnesota
- Praxis Research Site - Minneapolis
New Jersey
- Praxis Research Site - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2023-08-02 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
What the registry record for NCT05818553 still lists
NCT05818553 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower).
The record links to 2 conditions, with SCN2A Encephalopathy appearing as the primary indexed condition, and to 1 intervention - of which PRAX-562 is the first listed.
NCT05818553 lists 8 locations in 5 states (Other, Georgia, Illinois).
Frequently Asked Questions
What is clinical trial NCT05818553 about?
NCT05818553 is a clinical study titled "A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)". A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)
What is the current status of trial NCT05818553?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2023-08-02. Estimated completion is 2027-03-01.
What conditions does trial NCT05818553 study?
This clinical trial studies the following conditions: SCN2A Encephalopathy, SCN8A Encephalopathy.
What interventions are being tested in trial NCT05818553?
The interventions under investigation include: PRAX-562 (DRUG).
Who is sponsoring clinical trial NCT05818553?
This trial is sponsored by Praxis Precision Medicines, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05818553 being conducted?
This trial has 8 study locations across Georgia, Illinois, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SCN2A Encephalopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05818553's enrollment target sits among peer trials
77 891st of 2000 higher than 1,108 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI